Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00840866 · ClinicalTrials.gov registry record · Phase 1

Cefprozil 500 mg Tablets Under Fed Conditions

A Phase 1 study, sponsored by Teva Pharmaceuticals USA.

Completed
Registry status
Phase 1
Development phase
39
Enrollment target

NCT00840866: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.

NCT00840866 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 39 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00840866, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.

COMPLETED
Registry status
Phase 1
Development phase
39 participants
Enrollment target

Study Summary

The objective of this study is to compare the relative bioavailability of cefprozil 500 mg tablets with that of Cefzil 500 mg tablets in healthy, non-smoking adults under non-fasting conditions.

Primary Outcome

Bioequivalence based on Cmax.

Interventions

  • DRUG cefprozil
  • DRUG Cefzil®

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2003-09
Est. Completion 2003-09
Phase Phase 1
Teva Pharmaceuticals USA

83 total trials

What the finished NCT00840866 record still lists

NCT00840866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower).

The record links to 0 conditions, and to 2 interventions - of which cefprozil is the first listed.

NCT00840866 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00840866 about?

NCT00840866 is a clinical study titled "Cefprozil 500 mg Tablets Under Fed Conditions". The objective of this study is to compare the relative bioavailability of cefprozil 500 mg tablets with that of Cefzil 500 mg tablets in healthy, non-smoking adults under non-fasting conditions.

What is the current status of trial NCT00840866?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2003-09. Estimated completion is 2003-09.

What interventions are being tested in trial NCT00840866?

The interventions under investigation include: cefprozil (DRUG), Cefzil® (DRUG).

Who is sponsoring clinical trial NCT00840866?

This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00840866's enrollment target sits among peer trials

39 1191st of 2000 higher than 804 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03465592 · 39 participants · Phase 1

    Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

  • NCT03961776 · 39 participants

    Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

  • NCT04050280 · 39 participants · Phase 2

    CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

  • NCT04190862 · 39 participants · Phase 1

    E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00840866, the US trial registry maintained by the National Library of Medicine. NCT00840866 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.